YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)


AddThis Social Bookmark Button

Injured by Reminyl?

Data from two clinical trials indicated that people taking Reminyl (Generic: Galantamine) have a much higher death rate than those taking a placebo. Reminyl is an Alzheimer's disease drug. The review was announced on 1/21/05 by Johnson & Johnson, which said it's in discussions with the Food and Drug Administration and regulators in Europe and Canada.

The trials, involved approximately 2,000 patients in 16 countries. were looking if Reminyl could be used to treat mild cognitive impairment, a form of memory loss that is often associated with Alzheimer's. Reminyl is approved in 69 countries as a treatment for mild to moderate Alzheimer's but not for mild cognitive impairment. In the trials, which lasted two years, 15 patients taking Reminyl died compared with 5 taking the placebo.

The announcement comes at a time of heightened concern over the safety of widely used drugs after the withdrawal from the market of Merck's pain reliever, Vioxx, which studies indicated posed an increased risk of heart attacks and strokes. Johnson & Johnson responded by saying that the overall number of deaths in the trials was low for the elderly population in the trial and that the incidence of serious side effects was the same for patients getting the drug and the placebo. Also, it said, the investigators in the trials had not thought the drug caused any of the deaths.

Reminyl was approved on the basis of six-month studies but the mild cognitive impairment trials lasted two years, increasing their chances of detecting side effects. Nevertheless, the Johnson & Johnson analysis said the excess of deaths in the mild cognitive impairment trials was evident by six months, while no such excess was seen in the Alzheimer's trials.

Reminyl was developed with Shire Pharmaceuticals of Britain. Sales for Johnson & Johnson are estimated at about $200 million a year. Public Citizen, the watchdog group, recommends against using Reminyl or other drugs in its class, saying they have minimal benefit and the effectiveness and safety of taking them longer than six months is not known, according to Sidney Wolfe, director of health research.

If you or a loved one took Reminyl and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney.
ReminylRSS Feed

Pharmacies Ignore Pullout Order, Sell Harmful Ophthalmic Solution

Jun 26, 2006 | www.arabnews.com
Despite the announcement a month ago by the manufacturers of a highly harmful ophthalmic solution that they were recalling the product, the item is still available in pharmacies across Jeddah. Bausch & Lomb, the manufacturers of the contact lens clearing solution ReNu with MoistureLoc, announced their decision to call back the product from markets worldwide due to a high rate of eye infection associated with it. The Saudi Ministry of Health also issued a precautionary note around the same...

Reminyl (galantamine) Precautions due to Deaths Reported in Clinical Trials

Apr 1, 2005 | www.pharmalive.com
Ortho-McNeil Neurologics modified the PRECAUTIONS section of the Prescribing Information for Reminyl, approved only for the treatment of mild to moderate Alzheimer's Disease. The changes provide new safety information regarding the results of two randomized, placebo-controlled trials of 2 years duration in subjects with mild cognitive impairment(MCI). A total of 13 subjects on REMINYL (n=1026) and 1 subject on placebo (n=1022) died. The deaths were due to various causes which could be expected...

Trials Show Higher Death Rate Among Some Test Subjects Using Reminyl

Jan 22, 2005 | AP
Patients taking Alzheimer's drug Reminyl in a test for another use had higher death rates than those taking a placebo, Johnson & Johnson Pharmaceutical Research & Development LLC announced Friday. The patients had mild cognitive impairment, and the J&J company is no longer pursuing Reminyl as a treatment for the condition and has not submitted any applications for such use, spokeswoman Carol Goodrich said. Reminyl was approved in 2001 as a treatment for mild to moderate Alzheimer's disease. The...

More Reminyl News

Reminyl
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | ReNu with MoistureLoc | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2008 YourLawyer.com. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News